Strengthening the pipeline for innovation in cancer research: The National Cancer Institute's program for Innovative Molecular Analysis Technologies

Abstract

The declining value of the dollar and the evolving shape of the economy are affecting the value and availability of the funds that support the development and commercialization of novel cancer technologies. This conservatism goes against the forward advance of translational science, which is beginning to show its greatest promise for the pursuit of innovation and the dissemination of emerging technologies. Cancer technology development is nearing a tipping point in which these countering trends may result in a decline of the United States' ability to encourage and foster innovation. The National Cancer Institute's Innovative Molecular Analysis Technologies (IMAT) program is attempting to address this rapidly changing environment to ensure that innovation is not stifled. Discussed is an overview of the IMAT program, identified bottlenecks for innovation, and a proposed strategy for engaging new partners to strengthen the pipeline for innovative cancer technologies.